ONCOSIL MEDICAL LIMITED ASX Announcement
2 May 2022
For personal use only
Clarification of Non-Renounceable Entitlement Offer Details
Sydney, Australia - 2 May 2022: OncoSil Medical Ltd (ASX: OSL) (OncoSil or the Company) is responding to numerous queries from shareholders in relation to the upcoming Non-Renounceable Entitlement Offer (Offer) by providing a summary of the key dates for the Offer and other important information.
To be eligible to participate in the upcoming Offer, shares must be held in OncoSil by the record date, Friday 6 May 2022.
Authorisation & Additional Information
This announcement was authorised by the Board of Directors of OncoSil Medical Limited.
About OncoSil
OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.
Treatment with the OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted six clinical studies with positive results on tolerability, safety and efficacy. CE Marking has been granted for the OncoSil™ device which can be marketed in the European Union and the United Kingdom. The OncoSil™ device has also been classified a Breakthrough Device in the European Union and the United Kingdom.
An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval.
In December 2018, the FDA granted Humanitarian Use Designation (HUD) for the OncoSil™ device for the treatment of unresectable bile duct cancer. In March 2020, the FDA granted Breakthrough Device Designation for the OncoSil™ for unresectable pancreatic cancer in conjunction with systemic chemotherapy.
Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds $3b.
Forward Looking Statements
This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing
ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL
Suite 503, Level 5, 15 Blue Street, North Sydney, NSW 2060 AUSTRALIA TELEPHONE +61 2 9223 3344 FACSIMILE +61 2 9252 3988
pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
For personal use only
OncoSil Medical is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.
ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL
Suite 503, Level 5, 15 Blue Street, North Sydney, NSW 2060 AUSTRALIA TELEPHONE +61 2 9223 3344 FACSIMILE +61 2 9252 3988
ersonal use only
Non-Renounceable Rights Issue & Top Up Facility
2 May 2022
Disclaimer
ersonal use only
This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) and is provided for general information purposes only. No party other than OncoSil has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.
This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. OncoSil makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. OncoSil and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.
This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.
This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of OncoSil. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.
2 • Non-Renounceable Rights Issue & Top Up Facility• 2 May 2022
Company Overview
ersonal use only
Board of Directors | |||
Otto Buttula | Nigel Lange | Ricky Sharma | Martin Cross |
Non-Executive Chairman | Managing Director and CEO | Non-Executive Director | Non-Executive Director |
|
|
|
|
Capital Structure | |
ASX Code | OSL |
Share Price (at 29 April 2022) | $0.058 |
Shares on Issue | 792,343,294 |
Market Capitalisation | $39.6m |
Cash in bank (31 March 2022) | $4.06m |
Top 20 shareholders | 29.4% |
3 • Non-Renounceable Rights Issue & Top Up Facility• 2 May 2022
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
OncoSil Medical Ltd. published this content on 01 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 May 2022 23:36:03 UTC.
